MEDIPOST Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 2000-01-01
- Employees
- 290
- Market Cap
- -
- Website
- http://www.medi-post.co.kr
Advancements in Bronchopulmonary Dysplasia Treatment: A Look into the 2024 Pipeline
The 2024 Bronchopulmonary Dysplasia (BPD) pipeline showcases significant progress with over 12 companies developing therapies. Key developments include Airway Therapeutics, Inc.'s Phase 3 trial for zelpultide alfa and Chiesi Farmaceutici SpA's collaboration with Oak Hill Bio on OHB-607. These efforts aim to address the unmet needs in BPD treatment, particularly for preterm infants.
© Copyright 2025. All Rights Reserved by MedPath